%PDF-1.7
%
1 0 obj
<>>>
endobj
2 0 obj
<>stream
2020-03-17T12:24:45-04:00
2020-03-17T12:24:48-04:00
2020-03-17T12:24:48-04:00
Adobe InDesign CC 13.1 (Windows)
uuid:bda254b4-5b68-49a5-8c83-b0cdb5daf330
xmp.did:4A42F9656056E111960DCE8E95F0DF9D
xmp.id:37411c7f-fbf3-8147-af89-5ae98423c89c
proof:pdf
xmp.iid:0fe2f47a-99e5-5743-b065-6fb676a13e05
xmp.did:c340c662-41b6-0243-b4a3-2f3453a84d88
xmp.did:4A42F9656056E111960DCE8E95F0DF9D
default
converted
from application/x-indesign to application/pdf
Adobe InDesign CC 13.1 (Windows)
/
2020-03-17T12:24:45-04:00
application/pdf
Adobe PDF Library 15.0
False
endstream
endobj
12 0 obj
<>
endobj
3 0 obj
<>
endobj
5 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
6 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
7 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
8 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
9 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
10 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
11 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
14 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
40 0 obj
<>stream
q
/GS0 gs
0 TL/Fm0 Do
Q
BT
/CS0 cs 1 scn
/GS0 gs
/T1_0 1 Tf
-0.01 Tc 8.5 0 0 8.5 171.2281 247.398 Tm
(1.)Tj
/Span<>> BDC
[( )-94.4 ( )]TJ
EMC
1.588 0 Td
[(Which statement regarding epidural steroid)-10 ( )]TJ
0 -1.2 Td
(injection \(ESI\) is correct?)Tj
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
0 -1.2 Td
[(a. ESI is cost-effective at the three-month)-10 ( )]TJ
0 -1.2 Td
(follow-up period.)Tj
0 -1.2 Td
(b. ESI is cost-effective at the six-month follow-)Tj
0 -1.2 Td
(up period.)Tj
0 -1.2 Td
[(c. ESI is better than medical management at)-10 ( )]TJ
0 -1.2 Td
(three months.)Tj
0 -1.2 Td
[(d. Neither ESI nor medical management)-10 ( )]TJ
-0.007 Tw 0 -1.2 Td
[(provides signi\037cant quality of life improvement)-10 ( )]TJ
0 Tw 0 -1.2 Td
(over baseline at six months.)Tj
/CS0 cs 1 scn
/GS0 gs
/T1_0 1 Tf
-1.588 -2.4 Td
(2.)Tj
/Span<>> BDC
[( )-94.4 ( )]TJ
EMC
1.588 0 Td
[(In the study by Khezri et al, participants in the)-10 ( )]TJ
0 -1.2 Td
[(apple cider vinegar group had a statistically)-10 ( )]TJ
0 -1.2 Td
(signi\037cant reduction in:)Tj
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
22.896 16.8 Td
(a. high-density lipoprotein cholesterol.)Tj
0 -1.2 Td
[(b. physical activity)92 (.)]TJ
0 -1.2 Td
(c. body mass index.)Tj
0 -1.2 Td
[(d. plasma concentration of neuropeptide-Y)129 (.)]TJ
/CS0 cs 1 scn
/GS0 gs
/T1_0 1 Tf
-1.588 -2.894 Td
(3.)Tj
/Span<>> BDC
[( )-94.4 ( )]TJ
EMC
1.588 0 Td
[(An independent predictor of all-cause)-10 ( )]TJ
0 -1.2 Td
[(mortality in patients followed medically)-10 ( )]TJ
0 -1.2 Td
[(for chronic moderate to severe aortic valve)-10 ( )]TJ
0 -1.2 Td
(regurgitation is:)Tj
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
0 -1.2 Td
(a. resting bradycardia.)Tj
0 -1.2 Td
(b. diastolic blood pressure < 70 mmHg.)Tj
0 -1.2 Td
(c. systolic blood pressure > 140 mmHg.)Tj
0 -1.2 Td
(d. pulse pressure < 40 mmHg.)Tj
ET
0 0 0 0.2 K
13 w
/GS0 gs
q 1 0 0 1 244.2455 660.9166 cm
0 0 m
105.239 0 l
S
Q
q 1 0 0 1 163.5162 648.856 cm
0 0 m
171.149 0 l
S
Q
q 1 0 0 1 163.5162 636.7954 cm
0 0 m
189.238 0 l
S
Q
q 1 0 0 1 163.5162 624.7349 cm
0 0 m
177.129 0 l
S
Q
q 1 0 0 1 163.5162 612.6743 cm
0 0 m
180.998 0 l
S
Q
q 1 0 0 1 163.5162 600.6137 cm
0 0 m
182.908 0 l
S
Q
q 1 0 0 1 163.5162 588.5531 cm
0 0 m
173.748 0 l
S
Q
q 1 0 0 1 163.5162 576.4926 cm
0 0 m
179.798 0 l
S
Q
q 1 0 0 1 163.5162 564.432 cm
0 0 m
124.389 0 l
S
Q
q 1 0 0 1 253.835 443.8263 cm
0 0 m
66.349 0 l
S
Q
q 1 0 0 1 163.5162 431.7657 cm
0 0 m
189.238 0 l
S
Q
q 1 0 0 1 163.5162 419.7051 cm
0 0 m
183.259 0 l
S
Q
q 1 0 0 1 163.5162 407.6446 cm
0 0 m
177.168 0 l
S
Q
q 1 0 0 1 163.5162 395.584 cm
0 0 m
173.578 0 l
S
Q
q 1 0 0 1 163.5162 383.5234 cm
0 0 m
183.799 0 l
S
Q
q 1 0 0 1 163.5162 371.4629 cm
0 0 m
48.249 0 l
S
Q
q 1 0 0 1 163.5162 335.2811 cm
0 0 m
182.668 0 l
S
Q
q 1 0 0 1 163.5162 323.2206 cm
0 0 m
151.958 0 l
S
Q
q 1 0 0 1 163.5162 311.16 cm
0 0 m
124.889 0 l
S
Q
BT
/GS1 gs
-0.03 Tc 10 0 0 10 163.5162 730.28 Tm
[(with primarily ASCVD \(94-98%; 3-6%)-30 ( )]TJ
0 -1.206 Td
[(with HeFH\) and on maximally tolerated)-30 ( )]TJ
0 -1.206 Td
[(lipid-lowering therapy)92 (.)]TJ
0.03 Tw 5.83 0 0 5.83 254.6156 709.4888 Tm
(1,5,6)Tj
0 Tw 10 0 0 10 266.707 706.1588 Tm
[( Subjects were)-30 ( )]TJ
-10.319 -1.206 Td
[(randomized to bempedoic acid \(n = 2,010\) or)-30 ( )]TJ
0 -1.206 Td
[(placebo \(n = 999\), with the primary ef\037cacy)-30 ( )]TJ
0 -1.206 Td
[(endpoint of percent change from baseline to)-30 ( )]TJ
0 -1.206 Td
(week 12 in LDL-C. )Tj
[(In trial 1, bempedoic acid)-30 ( )]TJ
0 -1.206 Td
[(showed a mean LDL-C reduction of 18%)-30 ( )]TJ
-0.001 Tw 0 -1.206 Td
(from placebo from a baseline mean of 103 mg/)Tj
0 Tw 0 -1.206 Td
[(dL. In trial 2, the mean reduction was 17%)-30 ( )]TJ
0 -1.206 Td
[(from a mean baseline of 120 mg/dL. In both)-30 ( )]TJ
0 -1.206 Td
[(studies, non-LDL-C, apo B, total cholesterol,)-30 ( )]TJ
0 -1.206 Td
[(and high-sensitivity C-reactive protein also)-30 ( )]TJ
0 -1.206 Td
[(were reduced signi\037cantly)92.1 (. Those reductions)-29.9 ( )]TJ
0 -1.206 Td
(were maintained for 52 weeks.)Tj
0 Tc 12.439 0 Td
( )Tj
-0.03 Tc -12.439 -2.412 Td
[(The \037xed combination of bempedoic acid)-30 ( )]TJ
0 -1.206 Td
[(and ezetimibe was evaluated in a randomized,)-30 ( )]TJ
0 -1.206 Td
[(double-blind, four)55 (-arm study that included)-30 ( )]TJ
0 -1.206 Td
[(301 subjects with HeFH, established ASCVD,)-30 ( )]TJ
0 -1.206 Td
[(or multiple risk factors for CV disease and)-30 ( )]TJ
0 -1.206 Td
(mean LDL-C of 150 mg/dL.)Tj
0.03 Tw 5.83 0 0 5.83 277.4252 480.338 Tm
(1,7)Tj
0 Tw 10 0 0 10 285.0042 477.008 Tm
[( Subjects)-29.9 ( )]TJ
-12.149 -1.206 Td
[(were randomized to bempedoic acid \(180)-30 ( )]TJ
0 -1.206 Td
(mg\), ezetimibe \(10 mg\), bempedoic acid/)Tj
0 -1.206 Td
(ezetimibe, or placebo. )Tj
(Bempedoic acid/)Tj
0 -1.206 Td
[(ezetimibe provided a 38% reduction in LDL-C)-30 ( )]TJ
0 -1.206 Td
[(compared to placebo, with 34% exhibiting a)-30 ( )]TJ
0 -1.206 Td
[(greater than 50% reduction in LDL-C. The)-30 ( )]TJ
0 -1.206 Td
[(LDL-C reductions for bempedoic acid and)-30 ( )]TJ
0 -1.206 Td
[(ezetimibe individually were -19% and -25%,)-30 ( )]TJ
0.03 Tw 0 -1.206 Td
[(respectively)92 (.)]TJ
/TT0 1 Tf
0.025 Tc 0 Tw 0 -2.412 Td
[(CLINICAL IMPLICA)72.7 (TIONS)]TJ
/T1_1 1 Tf
-0.03 Tc 0 -1.206 Td
[(Bempedoic acid provides a modest reduction)-30 ( )]TJ
0 -1.206 Td
[(in LDL-C and is much more effective)-30 ( )]TJ
0 -1.206 Td
(in combination with ezetimibe.)Tj
[( LDL-C)-30 ( )]TJ
ET
/GS0 gs
q 1 0 0 1 538.9619 550.8967 cm
0 0 m
16.529 0 l
S
Q
q 1 0 0 1 366.2537 538.7378 cm
0 0 m
181.858 0 l
S
Q
q 1 0 0 1 366.2537 526.5789 cm
0 0 m
107.709 0 l
S
Q
BT
/GS1 gs
10 0 0 10 366.2537 730.28 Tm
[(reductions seen with proprotein convertase)-29.9 ( )]TJ
0 -1.216 Td
[(subtilisin/kexin type 9 monoclonal antibodies)-30 ( )]TJ
0 -1.216 Td
[(inhibitors \(e.g., evolocumab, alirocumab\))-30 ( )]TJ
0 -1.216 Td
[(when added to maximally tolerated statins)-30 ( )]TJ
0 -1.216 Td
[(ranged from 60% to 70%, along with)-30 ( )]TJ
0 -1.216 Td
(reduction in risk of CV events.)Tj
0.03 Tw 5.83 0 0 5.83 489.2123 672.8156 Tm
(8,9)Tj
0 Tw 10 0 0 10 496.7912 669.4855 Tm
[( The)-30 ( )]TJ
-13.054 -1.216 Td
[(effect of bempedoic acid monotherapy or)-29.9 ( )]TJ
0 -1.216 Td
[(in a \037xed combination with ezetimibe on)-30 ( )]TJ
0 -1.216 Td
[(cardiovascular morbidity and mortality has)-30 ( )]TJ
0 -1.216 Td
(not been determined. An ongoing placebo-)Tj
0 -1.216 Td
[(controlled trial with bempedoic acid in 12,600)-30 ( )]TJ
0 -1.216 Td
[(subjects will evaluate the occurrence of major)-30 ( )]TJ
0 -1.216 Td
[(cardiovascular events in patients with, or)-30 ( )]TJ
0 -1.216 Td
[(at high risk for)111 (, cardiovascular disease who)-30 ( )]TJ
0 -1.216 Td
[(are statin-intolerant \(NCT02993406\). The)-30 ( )]TJ
0 -1.216 Td
(estimated completion date is March 2022. )Tj
0.03 Tw [(The)-29.9 ( )]TJ
0 Tw 0 -1.216 Td
(cost for bempedoic acid and bempedoic acid/)Tj
0 -1.216 Td
(ezetimibe is $11 per tablet.)Tj
0 Tc -0.03 Tw ( )Tj
/C2_0 1 Tf
0 Tw 11.297 0 Td
<0084>Tj
/TT0 1 Tf
0.01 Tc -0.01 Tw 9.25 0 0 9.25 366.2537 497.8611 Tm
(REFERENCES)Tj
/TT1 1 Tf
-0.03 Tc 0 Tw 0 -1.206 Td
(1.)Tj
/Span<>> BDC
( )Tj
EMC
1.946 0 Td
[(Esperion Therapeutics, Inc. Nexletol P)35.7 (rescribing)-29.9 ( )]TJ
0 -1.206 Td
[(Information, F)35.8 (ebruary 2020. Available at:)-29.9 ( )]TJ
0 Tc 14.547 0 Td
( )Tj
-0.03 Tc 0.03 Tw -14.547 -1.206 Td
(http://bit.ly/2Q8nfJ9.)Tj
0 Tw -1.946 -1.206 Td
(2.)Tj
/Span<>> BDC
( )Tj
EMC
1.946 0 Td
[(P)17.6 (inkosky SL, et al. )]TJ
/TT2 1 Tf
(Nat Commun)Tj
/TT1 1 Tf
( 2016;7:13457.)Tj
-1.946 -1.206 Td
(3.)Tj
/Span<>> BDC
( )Tj
EMC
1.946 0 Td
[(Esperion Therapeutics, Inc. Nexlizet P)35.7 (rescribing)-29.9 ( )]TJ
0 -1.206 Td
[(Information, F)35.8 (ebruary 2020. Available at:)-29.9 ( )]TJ
0 Tc 14.547 0 Td
( )Tj
-0.03 Tc 0.03 Tw -14.547 -1.206 Td
[(http://bit.ly/2Q8A)17.6 (O)35.8 (YX.)]TJ
0 Tw -1.946 -1.206 Td
(4.)Tj
/Span<>> BDC
( )Tj
EMC
1.946 0 Td
[(T)174.8 (omaszewski M1, et al. )]TJ
/TT2 1 Tf
(Pharmacol Rep)Tj
/TT1 1 Tf
0 Tc 13.638 0 Td
( )Tj
-0.03 Tc 0.03 Tw -13.638 -1.206 Td
(2011;63:859-866.)Tj
0 Tw -1.946 -1.206 Td
(5.)Tj
/Span<>> BDC
( )Tj
EMC
1.946 0 Td
[(R)-36.7 (ay KK, et al. )]TJ
/TT2 1 Tf
(N Engl J Med)Tj
/TT1 1 Tf
( 2019;380:1022-1032.)Tj
-1.946 -1.206 Td
(6.)Tj
/Span<>> BDC
( )Tj
EMC
1.946 0 Td
[(Goldberg A)17.6 (C, et al. )]TJ
/TT2 1 Tf
0.03 Tw (JAMA)Tj
/TT1 1 Tf
0 Tw ( 2019;322:1780-1788.)Tj
-1.946 -1.206 Td
(7.)Tj
/Span<>> BDC
( )Tj
EMC
1.946 0 Td
(Ballantyne CM, et al. )Tj
/TT2 1 Tf
[(Eur J P)35.6 (rev Cardiol)]TJ
/TT1 1 Tf
0 Tc 13.322 0 Td
( )Tj
-0.03 Tc 0.03 Tw -13.322 -1.206 Td
(2019;2047487319864671.)Tj
0 Tw -1.946 -1.206 Td
(8.)Tj
/Span<>> BDC
( )Tj
EMC
1.946 0 Td
[(Amgen Inc. R)17.5 (epatha P)35.7 (rescribing Information,)-29.9 ( )]TJ
0 -1.206 Td
[(F)35.9 (ebruary 2019. Available at: http://bit.ly/3aPJJ9w)72.9 (.)]TJ
-1.946 -1.206 Td
(9.)Tj
/Span<>> BDC
( )Tj
EMC
1.946 0 Td
[(Sanofi US Group. P)35.7 (raluent P)35.7 (rescribing Information,)-29.9 ( )]TJ
0 -1.206 Td
[(April 2019. Available at: http://bit.ly/2IA)17.6 (UuR8.)]TJ
ET
endstream
endobj
41 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Subtype/Form>>stream
/CS0 cs 0.07 scn
/GS0 gs
18 97.92 120.33 658.08 re
f
18 36 539.325 53.473 re
f
BT
0 0 0 1 k
/GS1 gs
/TT0 1 Tf
0 Tc 0 Tw 0 Ts 100 Tz 0 Tr 7 0 0 7 27.8983 78.3659 Tm
(Interested in reprints or posting an article to your )Tj
0 -1.143 Td
[(company)-55.8 (\222s site? There are numerous opportunities for )]TJ
0 -1.143 Td
(you to leverage editorial recognition for the benefit of )Tj
0 -1.143 Td
(your brand. Call us at \(800\) 688-2421 or email us at )Tj
0 -1.143 Td
(reprints@reliasmedia.com.)Tj
25.217 4.571 Td
(Discounts are available for group subscriptions, multiple )Tj
0 -1.143 Td
(copies, site licenses, or electronic distribution. For pricing )Tj
0 -1.143 Td
(information, please contact our Group Account Managers )Tj
0 -1.143 Td
(at groups@reliasmedia.com or \(866\) 213-0844.)Tj
19.248 0 Td
( )Tj
5.969 3.429 Td
[(T)175 (o reproduce any part of R)17.6 (elias Media newsletters for )]TJ
0 -1.143 Td
(educational purposes, please contact The Copyright )Tj
0 -1.143 Td
(Clearance Center for permission at info@copyright.com )Tj
0 -1.143 Td
(or \(978\) 750-8400.)Tj
ET
/CS0 CS 1 SCN
3 w 4 M 0 j 0 J
/GS0 gs
q 1 0 0 1 138.6633 754.5 cm
0 0 m
437.337 0 l
S
Q
/CS0 cs 1 scn
163.328 262.513 392.414 18.174 re
f
0.25 w
163.391 98.045 392.225 164.63 re
S
BT
0 scn
0.037 Tc -0.012 Tw 10 0 0 10 318.7734 268.7422 Tm
[(C)-3.7 (M)-3 (E)12 ( Q)1.9 (U)-3.3 (E)5.9 (S)4.8 (T)10.1 (ION)-11.3 (S)]TJ
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
0 Tc 0 Tw 6 0 0 6 25.2 744.168 Tm
(PHYSICIAN EDITOR)Tj
/TT0 1 Tf
0 -1.167 Td
(Stephen A. Brunton, MD)Tj
/TT1 1 Tf
-0.025 Tc 0 -1.167 Td
[(Adjunct P)35.6 (rofessor of Pharmacy P)35.7 (ractice)]TJ
0 -1.167 Td
(College of Pharmacy)Tj
0 Tc 7.469 0 Td
( )Tj
-0.025 Tc -7.469 -1.167 Td
[(R)17.5 (oseman University of Health Sciences)]TJ
0 Tc 13.998 0 Td
( )Tj
-0.025 Tc -13.998 -1.167 Td
[(Salt L)17.4 (ake City)]TJ
/T1_0 1 Tf
0 Tc 0 -2.667 Td
(PEER REVIEWER)Tj
/TT0 1 Tf
0 -1.167 Td
[(Gerald R)17.7 (oberts, MD)]TJ
/TT1 1 Tf
0 -1.167 Td
(Senior Attending Physician )Tj
( )Tj
0 -1.167 Td
[(L)17.4 (ong Island Jewish Medical Center)]TJ
13.107 0 Td
( )Tj
-13.107 -1.167 Td
(NS/LIJ Health Care System)Tj
10.378 0 Td
( )Tj
-10.378 -1.167 Td
[(New Hyde P)54.8 (ark, NY)]TJ
/T1_0 1 Tf
0 -2.333 Td
[(EDITORIAL ADVISOR)92.1 (Y BOARD)]TJ
/TT0 1 Tf
0 -1.167 Td
(James Chan, PharmD, PhD)Tj
/TT1 1 Tf
0 -1.167 Td
[(Associate Clinical P)34.4 (rofessor)]TJ
( )Tj
0 -1.167 Td
(School of Pharmacy)Tj
7.563 0 Td
( )Tj
-7.563 -1.167 Td
(University of California)Tj
8.642 0 Td
( )Tj
-8.642 -1.167 Td
[(San F)54.9 (rancisco)]TJ
/TT0 1 Tf
0 -1.917 Td
[(William T)156.1 (. Elliott, MD, F)36.2 (A)17.5 (CP)]TJ
/TT1 1 Tf
0 -1.167 Td
[(Assistant Clinical P)33.9 (rofessor of Medicine )]TJ
0 -1.167 Td
(University of California)Tj
8.642 0 Td
( )Tj
-8.642 -1.167 Td
[(San F)54.9 (rancisco)]TJ
/TT0 1 Tf
0 -2.333 Td
(David Fiore, MD)Tj
/TT1 1 Tf
0 -1.167 Td
[(P)35.7 (rofessor of F)35.9 (amily Medicine)]TJ
0 -1.167 Td
(University of Nevada)Tj
( )Tj
0 -1.167 Td
[(R)17.5 (eno)]TJ
/TT0 1 Tf
0 -1.917 Td
[(K)17.7 (en Grauer)100.9 (, MD)]TJ
/TT1 1 Tf
0 -1.167 Td
[(P)35.7 (rofessor Emeritus in F)35.1 (amily )]TJ
( )Tj
0 -1.167 Td
(Medicine, College of Medicine,)Tj
0 -1.167 Td
(University of Florida)Tj
0 -1.167 Td
(Gainesville)Tj
/TT0 1 Tf
0 -2.333 Td
(Seema Gupta, MD, MSPH)Tj
/TT1 1 Tf
0 -1.167 Td
[(Clinical Assistant P)33.9 (rofessor)]TJ
0 -1.167 Td
[(Department of F)35.5 (amily )]TJ
( )Tj
0 -1.167 Td
(and Community Health)Tj
( )Tj
0 -1.167 Td
(Joan C. Edwards School of Medicine)Tj
0 -1.167 Td
(Marshall University)Tj
0 -1.167 Td
(Huntington, WV)Tj
/TT0 1 Tf
-0.01 Tc 0 -1.917 Td
[(Harold L. K)17.8 (arpman, MD, F)35.8 (A)17.5 (CC, F)35.7 (A)17.6 (CP)]TJ
/TT1 1 Tf
-0.03 Tc 0 -1.167 Td
[(Clinical P)35.7 (rofessor of Medicine)]TJ
0 Tc 10.349 0 Td
( )Tj
-0.03 Tc -10.349 -1.167 Td
(David Geffen School of Medicine)Tj
0 -1.167 Td
(University of California)Tj
0 Tc 7.952 0 Td
( )Tj
-0.03 Tc -7.952 -1.167 Td
[(L)17.4 (os Angeles)]TJ
/TT0 1 Tf
0 Tc 0 -1.917 Td
[(Louis K)17.8 (uritzky)87.5 (, MD)]TJ
/TT1 1 Tf
0 -1.167 Td
[(Clinical Assistant P)33.9 (rofessor )]TJ
0 -1.167 Td
(University of Florida)Tj
7.622 0 Td
( )Tj
-7.622 -1.167 Td
(Gainesville)Tj
/TT0 1 Tf
0 -1.917 Td
[(Martin S. Lipsky)87.5 (, MD)]TJ
/TT1 1 Tf
-0.03 Tc 0.03 Tw 0 -1.167 Td
(Chancellor)Tj
0 Tc 0 Tw 3.889 0 Td
( )Tj
-0.03 Tc -3.889 -1.167 Td
(South Jordan Campus)Tj
0 Tc 7.847 0 Td
( )Tj
-0.03 Tc -7.847 -1.167 Td
[(R)17.5 (oseman University of Health Sciences)]TJ
0 Tc 13.818 0 Td
( )Tj
-0.03 Tc -13.818 -1.167 Td
(South Jordan, UT)Tj
/TT0 1 Tf
0 Tc 0 -1.917 Td
[(Joseph E. Scherger)101.6 (, MD, MPH)]TJ
/TT1 1 Tf
0 -1.167 Td
[(Core F)35.8 (aculty)]TJ
0 -1.167 Td
[(Eisenhower Health F)35.5 (amily Medicine )]TJ
13.922 0 Td
( )Tj
-13.922 -1.167 Td
[(R)17.5 (esidency P)35.5 (rogram)]TJ
0 -1.167 Td
[(Eisenhower Health Center)99.9 (, L)17.5 (a Quinta, CA)]TJ
0 -1.167 Td
[(Clinical P)34.8 (rofessor)]TJ
0 -1.167 Td
[(K)17.6 (eck School of Medicine)]TJ
0 -1.167 Td
(University of Southern California)Tj
12.409 0 Td
( )Tj
-12.409 -1.167 Td
[(L)17.4 (os Angeles)]TJ
/TT0 1 Tf
0 -1.917 Td
(Allan J. Wilke, MD, MA)Tj
/TT1 1 Tf
0 -1.167 Td
[(P)35.7 (rofessor and Chair)]TJ
7.542 0 Td
( )Tj
-7.542 -1.167 Td
[(Department of F)35.5 (amily Medicine)]TJ
12.045 0 Td
( )Tj
-12.045 -1.167 Td
[(W)54.9 (estern Michigan University)]TJ
10.92 0 Td
( )Tj
-10.92 -1.167 Td
(School of Medicine)Tj
( )Tj
0 -1.167 Td
[(K)17.6 (alamazoo)]TJ
/T1_0 1 Tf
-0.01 Tc 0.01 Tw 0 -2.5 Td
(EDITOR)Tj
/TT0 1 Tf
0 Tw 0 -1.25 Td
(Jonathan Springston)Tj
/T1_0 1 Tf
0.01 Tw 0 -2.5 Td
(EDITOR)Tj
/TT0 1 Tf
0 Tw 0 -1.25 Td
(Jason Schneider)Tj
/T1_0 1 Tf
0 -2.5 Td
(EDITORIAL GROUP MANAGER)Tj
/TT0 1 Tf
0 -1.333 Td
(Leslie Coplin)Tj
/T1_0 1 Tf
0 -2.667 Td
[(ACCREDIT)74 (A)74 (TIONS MANAGER)]TJ
/TT0 1 Tf
0 -1.25 Td
(Amy M. Johnson, MSN, RN, CPN)Tj
ET
endstream
endobj
42 0 obj
<>
endobj
43 0 obj
<>
endobj
44 0 obj
<>
endobj
49 0 obj
<>
endobj
50 0 obj
<>stream
HdNV{q)>J\> i\?m 6eȷ<O/fst]~x{_Nϯ7ww˛oxx2r/?2އp?D??yz{qfzOt:m-_7͆"uDsF'OuOD'&2G'j~"7vG?j$O ?O'I?ɟ'$O ?O'I?ɟ'3,Ɵ?gYyV2ee*)U,S,XXVLbbY2Ų++*V(VTPXXQBbbE
ŊnL_//?R_/WU_W+*_WU_W+*_o7M7&o
o7M7&o
:zX.oز>*+zR9OS Mb
endstream
endobj
51 0 obj
<>stream
HtV TT[GamdY4(FBԸRhuXCܢE1Xbjj4`4#R%MXTړ3Ӝ}};Gҫ"MS"HshrVaec {Ӳj倰tV%cGTJo]dP$dd7f E{l)THGr؇y}IH9Usee(G=_o8r\_[Q08P hWRjwv-&0c]P-8ά8AQ8%旖 'ͬFcH́9T-?^%dQ}\\ܕ*@`P`No6`#GL1Cb>"~䋣^J|y?aM~5ii3g6;=Y9ܼ9sY痔-XX7/Yl+Vzrޮzgꍛ6彭|ܱsWmGgマR#9cO|~Mͧ